Omeros Corp
OMER3.715USD
+0.105+2.91%
取引時間 （ET）15分遅れの株価
215.71M時価総額
損失額直近12ヶ月PER
詳細情報 Omeros Corp 企業名
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
企業情報
企業コードOMER
会社名Omeros Corp
上場日Oct 08, 2009
最高経営責任者「CEO」DR. Gregory A. Demopulos, M.D.
従業員数202
証券種類Ordinary Share
決算期末Oct 08
本社所在地201 Elliott Avenue West
都市SEATTLE
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号98119
電話番号12066765000
ウェブサイトhttps://www.omeros.com/
企業コードOMER
上場日Oct 08, 2009
最高経営責任者「CEO」DR. Gregory A. Demopulos, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Thu, Jul 17
更新時刻: Thu, Jul 17
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
種類
株主統計
比率
Investment Advisor/Hedge Fund
16.95%
Investment Advisor
15.51%
Hedge Fund
3.93%
Individual Investor
3.84%
Research Firm
3.66%
Bank and Trust
0.89%
Insurance Company
0.13%
Pension Fund
0.10%
Other
55.00%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
251
30.23M
45.04%
-382.24K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
2023Q1
308
23.79M
37.88%
-4.75M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
4.02M
6.87%
+58.15K
+1.47%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
3.98M
6.79%
-30.05K
-0.75%
Mar 31, 2025
The Vanguard Group, Inc.
3.24M
5.53%
+95.60K
+3.04%
Mar 31, 2025
Demopulos (Gregory A. M.D.)
2.03M
3.46%
--
--
May 23, 2025
D. E. Shaw & Co., L.P.
1.94M
3.31%
+99.63K
+5.42%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
1.56M
2.66%
-24.56K
-1.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.37M
2.34%
+29.70K
+2.22%
Mar 31, 2025
State Street Global Advisors (US)
1.36M
2.31%
+144.57K
+11.93%
Mar 31, 2025
Corient Private Wealth LLC
720.42K
1.23%
-13.03K
-1.78%
Mar 31, 2025
Nomura Securities Co., Ltd.
679.02K
1.16%
-68.26K
-9.13%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Invesco NASDAQ Future Gen 200 ETF
0.44%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Invesco Dynamic Buyback Achievers ETF
0.01%
詳細を見る
Invesco NASDAQ Future Gen 200 ETF
比率0.44%
Vanguard US Momentum Factor ETF
比率0.12%
iShares Micro-Cap ETF
比率0.04%
ProShares Ultra Nasdaq Biotechnology
比率0.02%
Invesco Nasdaq Biotechnology ETF
比率0.02%
Invesco RAFI US 1500 Small-Mid ETF
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
Invesco Dynamic Buyback Achievers ETF
比率0.01%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
